Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Nov 22, 2022 10:38am
137 Views
Post# 35118589

RE:RE:RE:RE:RE:RE:Cantor report effect

RE:RE:RE:RE:RE:RE:Cantor report effectMost likely no news on the holiday weeks of Thanksgiving, Christmas and through to the new year….So just a short window in December left for good news, sure looking like my plan to hold out for positive news before selling some THTX for my RMD this year was a bad call :-<


jfm1330 wrote: Still no news. All we have is indirect signs that something positive is going on, like the Cantor report or the renewed job offer for a global regulatory manager in oncology. Again, why hiring somebody to fill this position if your oncology trial is not minimally positive at this point? How would you convince somebody to leave a good job somewhere else to accept the job with Thera, only to end up without a job in six months because the oncology trial is a total failure? In my view, you hire somebody for that job only if you see something minimally positive in the open label trial.


<< Previous
Bullboard Posts
Next >>